Guidelines for the Management of Unruptured Intracranial Aneurysm.
- Author:
Dae Hee SEO
1
;
Hyun Seung KANG
;
Dae Won KIM
;
Sukh Que PARK
;
Young SONG
;
Seung Hun SHEEN
;
Seung Hoon YOU
;
Sun Uk KWON
;
Joung Ho RHA
;
Hee Joon BAE
;
Chang Wan OH
;
Kyung Ho YU
;
Byung Woo YOON
;
Byung Chul LEE
;
Ji Hoe HEO
;
Keun Sik HONG
;
Seung Chyul HONG
;
In Sung PARK
Author Information
1. Department of Neurosurgery, Kwandong University College of Medicine, Myongji Hospital, Goyang, Korea.
- Publication Type:Review
- Keywords:
Unruptured Intracranial Aneurysm;
Guideline;
Natural History;
Diagnosis;
Management
- MeSH:
Aneurysm;
Calcium Hydroxide;
Delivery of Health Care;
Humans;
Intracranial Aneurysm;
Judgment;
Korea;
Light;
Natural History;
Risk Management;
Rupture;
Stroke;
Subarachnoid Hemorrhage;
Zinc Oxide
- From:Korean Journal of Cerebrovascular Surgery
2011;13(4):279-290
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Intracranial aneurysmal rupture causes subarachnoid hemorrhage which usually leads to fatality or severe disability. Treatment of unruptured intracranial aneurysms (UIAs) can substantially reduce the risk of rupture and prevent the grave consequences, but the risk of prophylactic treatment cannot be ignored. UIAs have diverse characteristics and management strategy needs to be tailored according to their location, size and clinical status. In the absence of level I evidence, the treatment guidance often relied on expert's opinions and experience. Knowledge of the natural course and management risks of individual aneurysms can help to guide treatment decision, but the natural history is still controversial and risks are not clearly defined. The Korean Society of Cerebrovascular Surgeons (KSCVS) decided to issue a Korean version of UIA management guideline as a framework for the treatment decision and as a basis for future studies, following 'Guideline Development Manual' of the Clinical Research Center for Stroke (CRCS). The organized committee systematically reviewed relevant literature and major guidelines published between January 2000 and July 2010 and took a developmental strategy of adaptation rather than de novo methods. On the basis of interpretation of the published evidences, recommendations were synthesized, and the level of evidence and the grade of recommendation were determined using the methods adapted from those of the US Agency for Healthcare Policy and Research and CRCS. The current guideline focuses on three domains of natural history, diagnosis and treatment of UIAs. The hierarchy of evidence and the recommendation grading indicate the current level by the literature and do not indicate the necessity or the prohibition of a certain clinical practice. Accordingly, this guideline cannot provide the answer for every clinical situation and should not take precedence over the clinical judgment of responsible physicians for individual patients. The final judgment regarding the care of a particular patient must be made by the physician and patient in light of circumstances specific to that patient. This is the first version of the UIA management guideline in Korea and new evidences will be timely and continuously updated in the future guidelines.
